{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"11.33","upperLimit":"14.29","value":"12.29"},{"groupId":"OG001","lowerLimit":"9.49","upperLimit":"11.76","value":"10.87"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"546"},{"groupId":"OG001","value":"542"}],"units":"Participants"}],"description":"The time interval from the date of randomization to the first date at which there was at least a 1 grade change (worsening) in the ECOG performance status grade. Participants who had no deterioration in ECOG performance status grade at the time of the analysis were censored at the last known date of no deterioration. ECOG is a 5-point scale, where 0=Fully active, 1=Ambulatory, carry out work of sedentary nature, 2=Ambulatory, capable of all self-care, 3=Capable of limited self-care, confined to bed or chair more than 50% of waking hours, 4=Completely disabled, no self-care, totally confined to bed or chair, 5=Dead. Participants with no assessment were censored at the date of randomization.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 1000 milligram (mg) abiraterone acetate tablets (as 4\\*250 mg tablets) orally once daily along with prednisone 5 mg tablet orally twice daily, from Day 1, Cycle1 (each cycle consist of 28 days) up to radiographic progression of disease and/or unequivocal clinical progression.","id":"OG000","title":"Abiraterone Acetate + Prednisone (AAP)"},{"description":"Participants received placebo matched to abiraterone acetate tablets orally once daily along with prednisone 5 mg tablet orally twice daily, from Day 1, Cycle1 (each cycle consist of 28 days) up to radiographic progression of disease and/or unequivocal clinical progression.","id":"OG001","title":"Placebo"}],"paramType":"MEDIAN","populationDescription":"ITT population included all the randomized participants who were classified according to their assigned treatment group, regardless of the actual treatment received.","reportingStatus":"POSTED","timeFrame":"From randomization (Day 1) up to first radiographic progression or cutoff date (Month 18)","title":"Time to Deterioration in Eastern Cooperative Oncology Group (ECOG) Performance Score by >=1 Point","type":"SECONDARY","unitOfMeasure":"Months"}